CY1119624T1 - Κρυσταλλικες μορφες του 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο] -3 -(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδιου - Google Patents

Κρυσταλλικες μορφες του 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο] -3 -(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδιου

Info

Publication number
CY1119624T1
CY1119624T1 CY20171100471T CY171100471T CY1119624T1 CY 1119624 T1 CY1119624 T1 CY 1119624T1 CY 20171100471 T CY20171100471 T CY 20171100471T CY 171100471 T CY171100471 T CY 171100471T CY 1119624 T1 CY1119624 T1 CY 1119624T1
Authority
CY
Cyprus
Prior art keywords
methyl
imidazol
pyridin
trifluoromethyl
phenyl
Prior art date
Application number
CY20171100471T
Other languages
English (en)
Inventor
Paul W. Manley
Wen-Chung Shieh
Paul Allen Sutton
Piotr H. Karpinski
Raeann Wu
Stéphanie MONNIER
Jörg Brozio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37451227&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119624(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1119624T1 publication Critical patent/CY1119624T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Κρυσταλλικές μορφές της ελεύθερης βάσης του 4-μεθυλο-Ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο]-3-(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδίου και των αλάτων του παρασκευάζονται διαμέσου διαφόρων μεθόδων.
CY20171100471T 2005-07-20 2017-04-26 Κρυσταλλικες μορφες του 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο] -3 -(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδιου CY1119624T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70140505P 2005-07-20 2005-07-20
US71621405P 2005-09-12 2005-09-12
EP06800109A EP1912973B1 (en) 2005-07-20 2006-07-18 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Publications (1)

Publication Number Publication Date
CY1119624T1 true CY1119624T1 (el) 2018-04-04

Family

ID=37451227

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100769T CY1113076T1 (el) 2005-07-20 2012-08-24 Κρυσταλλικες μορφες του 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο]-3-(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδιου
CY20171100471T CY1119624T1 (el) 2005-07-20 2017-04-26 Κρυσταλλικες μορφες του 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο] -3 -(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδιου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20121100769T CY1113076T1 (el) 2005-07-20 2012-08-24 Κρυσταλλικες μορφες του 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο]-3-(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδιου

Country Status (43)

Country Link
US (4) US8343984B2 (el)
EP (5) EP2284167B2 (el)
JP (3) JP5289948B2 (el)
KR (3) KR20130085444A (el)
CN (2) CN103804356A (el)
AR (1) AR054846A1 (el)
AU (3) AU2006276204A1 (el)
BR (1) BRPI0613615B1 (el)
CA (1) CA2614334C (el)
CR (1) CR9657A (el)
CU (1) CU23916B1 (el)
CY (2) CY1113076T1 (el)
DK (2) DK2284167T4 (el)
EA (2) EA016856B1 (el)
EC (1) ECSP088119A (el)
ES (3) ES2648288T3 (el)
GE (1) GEP20115302B (el)
GT (1) GT200600315A (el)
HK (1) HK1116783A1 (el)
HN (1) HN2008000311A (el)
HR (2) HRP20120573T1 (el)
HU (1) HUE031791T2 (el)
IL (2) IL188189A0 (el)
JO (1) JO3308B1 (el)
LT (1) LT2284167T (el)
MA (1) MA29626B1 (el)
MX (1) MX2008000899A (el)
MY (1) MY148554A (el)
NI (1) NI200800017A (el)
NO (1) NO341930B1 (el)
NZ (1) NZ564409A (el)
PE (1) PE20070214A1 (el)
PH (1) PH12013501590A1 (el)
PL (2) PL2284167T5 (el)
PT (2) PT1912973E (el)
RS (1) RS55929B2 (el)
SG (1) SG163620A1 (el)
SI (2) SI2284167T2 (el)
SM (1) SMAP200800011A (el)
TN (1) TNSN08029A1 (el)
TW (1) TWI406661B (el)
UA (1) UA94234C2 (el)
WO (1) WO2007015870A2 (el)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
AU2007235976A1 (en) * 2006-04-07 2007-10-18 Novartis Ag Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
WO2009082662A1 (en) 2007-12-21 2009-07-02 Novartis Ag Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia
WO2010009402A2 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
WO2010054056A2 (en) 2008-11-05 2010-05-14 Teva Pharmaceutical Industries Ltd. Nilotinib hci crystalline forms
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
CA2753637A1 (en) 2009-03-06 2010-09-10 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak)
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
RU2012120901A (ru) 2009-10-23 2013-12-10 Новартис Аг Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2011086541A1 (en) * 2010-01-15 2011-07-21 Generics [Uk] Limited Novel polymorph of nilotinib monohydrochloride monohydrate
WO2011128434A2 (en) 2010-04-16 2011-10-20 Novartis Ag Treatment of endocrine resistant breast cancer
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
KR20130042498A (ko) 2010-06-21 2013-04-26 테바 파마슈티컬 인더스트리즈 리미티드 닐로티닙 염 및 이의 결정형
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
US8703788B2 (en) * 2010-11-26 2014-04-22 Bandi Parthasaradhi Reddy Polymorph of nilotinib hydrochloride
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013063000A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
SG10201707768RA (en) 2011-11-14 2017-10-30 Novartis Ag Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
ES2564969T3 (es) * 2012-02-09 2016-03-30 Natco Pharma Limited Proceso para la preparación de clorhidrato de nilotinib
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
EP2872142A1 (en) 2012-07-11 2015-05-20 Novartis AG Method of treating gastrointestinal stromal tumors
US9376419B2 (en) 2012-10-15 2016-06-28 Apotex Inc. Solid forms of nilotinib hydrochloride
US9567317B2 (en) 2012-10-19 2017-02-14 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
CN105008357A (zh) * 2013-02-21 2015-10-28 辉瑞大药厂 选择性cdk4/6抑制剂的固态形式
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
EP3461818A1 (en) * 2013-04-24 2019-04-03 Dr. Reddy's Laboratories Ltd. Polymorphic forms of nilotinib hydrochloride
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
WO2016020891A1 (en) 2014-08-08 2016-02-11 Dr. Reddy’S Laboratories Limited Process for the preparation of polymorphic forms of nilotinib
WO2016058081A1 (en) * 2014-10-16 2016-04-21 Apotex Inc. Solid forms of nilotinib hydrochloride
EP3408264B1 (en) 2016-01-26 2020-03-11 Farma GRS, d.o.o. Nilotinib dinitrate (v) and crystalline forms thereof
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
DK3430004T3 (da) 2016-03-14 2020-09-28 Pliva Hrvatska D O O Faststofformer af nilotinibsalte
CN106496193A (zh) * 2016-09-13 2017-03-15 福格森（武汉）生物科技股份有限公司 一种高纯度尼罗替尼的制备方法
EP3404025B1 (en) 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
WO2019241504A1 (en) 2018-06-15 2019-12-19 Handa Pharmaceuticals, Llc Kinase inhibitor salts and compositions thereof
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法
US20210380557A1 (en) * 2018-11-05 2021-12-09 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
WO2022263510A1 (en) 2021-06-19 2022-12-22 Helm Ag Granulate composition comprising nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
CN116102540A (zh) * 2023-01-05 2023-05-12 浙江工业大学 两种尼洛替尼游离碱新晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701406A (en) 1901-07-16 1902-06-03 Thomas K Jones Cut-off-valve mechanism.
US701405A (en) 1902-02-17 1902-06-03 Archibald White Maconochie Ejecting device for stamping-machines.
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
SI1686997T1 (sl) * 2003-11-18 2009-08-31 Novartis Ag Inhibitorji mutantne oblike KIT
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Also Published As

Publication number Publication date
AU2012201453B2 (en) 2013-09-05
JP5289948B2 (ja) 2013-09-11
JO3308B1 (ar) 2018-09-16
WO2007015870A3 (en) 2007-06-07
EA016856B1 (ru) 2012-08-30
AU2012201453A1 (en) 2012-04-05
NO341930B1 (no) 2018-02-19
SI2284167T2 (sl) 2020-03-31
TNSN08029A1 (en) 2009-07-14
JP2013018789A (ja) 2013-01-31
PE20070214A1 (es) 2007-04-02
MA29626B1 (fr) 2008-07-01
KR20080027853A (ko) 2008-03-28
HRP20170634T4 (hr) 2020-02-07
JP5798101B2 (ja) 2015-10-21
EP2284168A3 (en) 2011-04-13
US20130023548A1 (en) 2013-01-24
KR20130085444A (ko) 2013-07-29
UA94234C2 (uk) 2011-04-26
SMP200800011B (it) 2008-02-27
PT2284167T (pt) 2017-05-15
HK1116783A1 (el) 2009-01-02
ES2648288T3 (es) 2017-12-29
EA013464B1 (ru) 2010-04-30
SI1912973T1 (sl) 2012-08-31
CA2614334C (en) 2015-04-21
US20140343087A1 (en) 2014-11-20
LT2284167T (lt) 2017-04-25
DK2284167T3 (en) 2017-05-01
DK1912973T3 (da) 2012-07-23
EP1912973B1 (en) 2012-06-13
US20080269269A1 (en) 2008-10-30
CR9657A (es) 2008-04-16
PH12013501590A1 (en) 2015-09-21
EP2543665A3 (en) 2013-05-29
AR054846A1 (es) 2007-07-18
SMAP200800011A (it) 2008-02-27
PL2284167T5 (pl) 2020-07-27
NO20080820L (no) 2008-04-15
PL2284167T3 (pl) 2017-07-31
US8343984B2 (en) 2013-01-01
US8415363B2 (en) 2013-04-09
SI2284167T1 (sl) 2017-05-31
BRPI0613615B1 (pt) 2022-02-08
EP1912973A2 (en) 2008-04-23
KR101651288B1 (ko) 2016-08-25
KR20130077915A (ko) 2013-07-09
GT200600315A (es) 2007-03-19
HRP20170634T1 (hr) 2017-06-30
EP2284167A3 (en) 2011-03-02
EP2284168A2 (en) 2011-02-16
HN2008000311A (es) 2011-01-24
CN102358736A (zh) 2012-02-22
US20130165465A1 (en) 2013-06-27
IL188189A0 (en) 2008-03-20
AU2006276204A1 (en) 2007-02-08
GEP20115302B (en) 2011-10-10
TWI406661B (zh) 2013-09-01
HRP20120573T1 (hr) 2012-08-31
ECSP088119A (es) 2008-02-20
US8829015B2 (en) 2014-09-09
JP2014221831A (ja) 2014-11-27
CU23916B1 (es) 2013-07-31
EA201000145A1 (ru) 2010-06-30
EP2284167A2 (en) 2011-02-16
NZ564409A (en) 2011-07-29
CU20080006A7 (es) 2011-02-24
CY1113076T1 (el) 2016-04-13
CA2614334A1 (en) 2007-02-08
RS55929B1 (sr) 2017-09-29
IL214659A0 (en) 2011-09-27
WO2007015870A2 (en) 2007-02-08
DK2284167T4 (da) 2020-03-02
ES2386974T3 (es) 2012-09-10
PL1912973T3 (pl) 2012-09-28
EP2535337B1 (en) 2017-08-23
JP2009502795A (ja) 2009-01-29
ES2623608T5 (es) 2020-06-18
RS55929B2 (sr) 2020-12-31
SG163620A1 (en) 2010-08-30
EP2284167B2 (en) 2019-11-27
AU2011202047A1 (en) 2011-05-26
TW200740793A (en) 2007-11-01
EP2535337A1 (en) 2012-12-19
MX2008000899A (es) 2008-03-18
NI200800017A (es) 2009-03-03
BRPI0613615A2 (pt) 2011-01-18
MY148554A (en) 2013-04-30
AU2012201453C1 (en) 2024-05-23
CN103804356A (zh) 2014-05-21
PT1912973E (pt) 2012-09-03
ES2623608T3 (es) 2017-07-11
EP2284167B1 (en) 2017-02-01
EP2543665A2 (en) 2013-01-09
EA200800201A1 (ru) 2008-06-30
HUE031791T2 (en) 2017-08-28

Similar Documents

Publication Publication Date Title
CY1119624T1 (el) Κρυσταλλικες μορφες του 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο] -3 -(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδιου
ECSP088118A (es) Sales de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
CY1109414T1 (el) Ν-σουλφονυλ πυρρολια και χρηση αυτων ως αναστολεις αποακετυλασης ιστονης
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
ATE471324T1 (de) Triazolophthalazine
EA200801430A1 (ru) Производные триазола
NO20073368L (no) Amid-promedikament av gemcitabin, sammensetninger og anvendelse derav
EA200801351A1 (ru) Фунгицидные смеси, которые содержат боскалид и пириметанил
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
EA201000618A1 (ru) 5-цианотиенопиридины для лечения опухолей
SE0301650D0 (sv) Novel compounds
CU20120123A7 (es) Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-il-pirimidin-2-il-amino)-benzamida
UY3516Q (es) Inhalador-rotahaler-m
UY3515Q (es) Parte superior inhalador-rotahaler-m-top